<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941460</url>
  </required_header>
  <id_info>
    <org_study_id>DIRECTOR</org_study_id>
    <secondary_id>2008-006871-60</secondary_id>
    <secondary_id>ISRCTN68738654</secondary_id>
    <nct_id>NCT00941460</nct_id>
  </id_info>
  <brief_title>Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma</brief_title>
  <acronym>DIRECTOR</acronym>
  <official_title>Dose-intensified Rechallenge With Temozolomide, One Week On One Week Off Versus Three Weeks On One Week Off in Patients With Progressive or Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Wolfgang Wick</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Essex Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with progressive or recurrent glioblastoma there is no standard therapy. One
      strategy is re-exposure to temozolomide in a higher dose. This increase in dosing can be done
      by 2 regimens. Aim of this study is to compare these 2 dosing regimens concerning toxicity.
      In study arm A patients receive temozolomide for one week, followed by a week without
      temozolomide. In study arm B patients receive temozolomide for three weeks, followed by a
      week without temozolomide. The regimen that is less toxic will be selected for further
      evaluations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median time to treatment failure. Treatment failure is reached (i) upon tumor progression as outlined in protocol (ii) if treatment has to be terminated due to toxicity or (iii) if the patient dies for any reason.</measure>
    <time_frame>up to one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>up to two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>one week on one week off</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One week on temozolomide is followed by a week without temozolomide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>three weeks on, one week off</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide is given over 3 weeks, followed by a week without temozolomide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide in both arms</intervention_name>
    <description>initial dose 120 mg/m2 in arm A</description>
    <arm_group_label>one week on one week off</arm_group_label>
    <other_name>Temodal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide in both arms</intervention_name>
    <description>initial dose 80 mg/m2 in arm B</description>
    <arm_group_label>three weeks on, one week off</arm_group_label>
    <other_name>Temodal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Progressive or recurrent glioblastoma documented by MRI no earlier than 180 days after
             first surgery for glioblastoma and no earlier than 90 days after completion of
             radiotherapy.

          -  Histological diagnosis of glioblastoma

          -  Tissue available for the determination of MGMT promoter methylation in the primary
             tumor or from the recurrent tumor if a patient undergoes a surgical procedure at
             recurrence prior to study entry.

          -  Prior treatment with temozolomide administered concomitantly with radiotherapy and at
             least for two cycles (5/28) as an adjuvant treatment

          -  Informed consent

          -  Age 18-80 years

          -  Karnofsky performance score &gt; 50%

          -  Neutrophil counts &gt; 1 500/µl

          -  Platelet counts &gt; 100 000/µl

          -  Hemoglobin &gt; 10 g/dl

          -  Serum creatinin &lt; 1.5-fold upper normal range

          -  ASAT or ALAT &lt; 3-fold upper normal range unless attributed to anticonvulsants

          -  Alkaline phosphatase &lt; 3-fold upper normal range

          -  Women with childbearing potential must have a negative serum pregnancy test ≤14 days
             prior to study enrollment

          -  Willingness to apply contraception according to local requirements (as stated in
             patient information)

        Exclusion Criteria:

          -  Progressive or recurrent glioblastoma documented by MRI earlier than 180 days after
             first surgery for glioblastoma and earlier than 90 days after completion of
             radiotherapy.

          -  Treatment with any chemotherapy other than temozolomide according to the schedule of
             the EORTC NCIC trial (Stupp et al. N Engl J Med 2005;352:987-996) except that an
             adjuvant starting dose of 200 mg/m2 and more than 6 cycles of adjuvant temozolomide
             are allowed

          -  Prior systemic or local treatment with DNA-damaging agents, tyrosine kinase inhibitors
             or anti-angiogenic agents for any cancer

          -  Allergy to or other intolerability of temozolomide

          -  Unable to undergo MRI

          -  Past medical history of diseases with poor prognosis, e.g. severe coronary heart
             disease, severe diabetes, immune deficiency, residual deficits after stroke, severe
             mental retardation

          -  HIV infection

          -  Pregnancy

          -  Breast feeding

          -  Treatment within in any other clinical trial parallel to the treatment phase of the
             current study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Weller, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landesnervenklinik Wagner-Jauregg</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna, Department of Internal Medicine I</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite, Department of Neurosurgery</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus, Department of Neurology</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn, Department of Neurology</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40001</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann-Wolfgang von Goethe-Universität, Dr. Senckenbergisches Institut für Neuroonkologie, Zentrum für Neurologie und Neurochirurgie</name>
      <address>
        <city>Frankfurt</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg, Department of Neurooncology</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saarland University, Department of Neurosurgery</name>
      <address>
        <city>Homburg/ Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Allgemeine Neurochirurgie</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Neurochirurgie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig Maximilians University of Munich , Grosshadern Hospital, Department of Neurosurgery</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Regensburg, Department of Neurology</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich, Department of Neurology</name>
      <address>
        <city>Zurich</city>
        <state>CH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois and University of Lausanne</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2009</study_first_submitted>
  <study_first_submitted_qc>July 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <last_update_submitted>August 13, 2014</last_update_submitted>
  <last_update_submitted_qc>August 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Wolfgang Wick</investigator_full_name>
    <investigator_title>Coordinating Investigator</investigator_title>
  </responsible_party>
  <keyword>progressive or recurrent glioblastoma</keyword>
  <keyword>temozolomide</keyword>
  <keyword>dose intensification</keyword>
  <keyword>comparison of two dosing regimens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

